Controlled release microparticle pharmaceutical composition for the sustained release of an EP2 receptor selective agonist for treating bone injury or bone defect

Disclosed is a use of an EP2 receptor selective agonist in the manufacture of a medicament for treating a bone fracture, bone injury or bone defect in a patient, wherein the medicament is adapted for local administration to the patient once a day for a period of about 7 days or greater, and wherein...

Full description

Saved in:
Bibliographic Details
Main Authors KORSMEYER, RICHARD WILKER, HONG, JINYANG, KIM, YESOOK, THOMPSON, DAVID DUANE, PARALKAR, VISHWAS MADHAV, DUMONT, FRANCIS, LI, MEI
Format Patent
LanguageEnglish
Published 31.05.2007
Edition7
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed is a use of an EP2 receptor selective agonist in the manufacture of a medicament for treating a bone fracture, bone injury or bone defect in a patient, wherein the medicament is adapted for local administration to the patient once a day for a period of about 7 days or greater, and wherein the EP2 receptor selective agonist is selected from the group of compounds defined in the specification.
Bibliography:Application Number: NZ20020532209